Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1546-1554

  Boccardo, F ^a,b   Guglielmini, P ^b   Bordonaro, R ^c   Fini, A ^d   Massidda, B ^e   Porpiglia, M ^f   Roagna, R ^f   Serra, P ^g   Orzalesi, L ^h   Ucci, G ⁱ   Rubagotti, A ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c S Luigi S Currò Hospital   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g Institute for Cancer Research   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ Clinical Pathology   (Italy)

Author keywords

Adjuvant therapy; Anastrozole; Breast cancer; Switching

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; DRUG SUBSTITUTION; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84876106789     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.025     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
2. M. Parton, and I.E. Smith Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women J Clin Oncol 26 2008 745 752 (Pubitemid 351264387)
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer V. 1.2012. National Comprehensive Cancer, Network; 2012.
4. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 2005 1652 1662 (Pubitemid 41672231)
5. E.A. Perez Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer Ann Oncol 18 S8 2007 viii26 viii35
6. M. Zilli, A. Grassadonia, and N. Tinari Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer J Natl Cancer Inst 96 2004 926 935
7. N. Normanno, M. Di Maio, and E. De Maio Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr Relat Cancer 12 2005 721 747 (Pubitemid 41815773)
8. I.E. Smith, and M. Dowsett Aromatase inhibitors in breast cancer N Engl J Med 348 2003 2431 2442 (Pubitemid 36682823)
9. A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
10. J. Cuzick, I. Sestak, and M. Baum Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 2010 1135 1141
11. H. Mouridsen, A. Giobbie-Hurder, and A. Goldhirsch Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
12. R.C. Coombes, L.S. Kilburn, and C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
13. F. Boccardo, A. Rubagotti, and M. Puntoni Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 23 2005 5138 5147 (Pubitemid 46224022)
14. M. Kaufmann, W. Jonat, and J. Hilfrich Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study J Clin Oncol 25 2007 2664 2670 (Pubitemid 47123171)
15. R. Jakesz, W. Jonat, and M. Gnant Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 2005 455 462 (Pubitemid 41111693)
16. M. Dowsett, J. Cuzick, and J. Ingle Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
17. W. Jonat, M. Gnant, and F. Boccardo Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Lancet Oncol 7 2006 991 996 (Pubitemid 44804137)
18. F. Boccardo, A. Rubagotti, and D. Amoroso Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study J Clin Oncol 19 2001 4209 4215 (Pubitemid 33081638)
19. F. Boccardo, A. Rubagotti, and P. Guglielmini Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 17 S7 2006 vii10 vii14
20. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
21. R. Peto, M.C. Pike, and P. Armitage Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II. Analysis and examples Br J Cancer 35 1977 1 39 (Pubitemid 8018922)
22. D.R. Cox Regression models and life tables J R Stat Soc 34 1972 187 220
23. R.J. Gray A class of k-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
24. S. Sharp, and J. Sterne Meta-analysis Stata Tech Bull 38 1997 9 14
25. J.M. Bliss, L.S. Kilburn, and R.E. Coleman Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study J. Clin Oncol 30 2012 709 717
26. E. Amir, B. Seruga, S. Niraula, L. Carlsson, and A. Ocaña Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis J Natl Cancer Inst 103 2011 1299 1309
27. P.C. Dubsky, R. Jakesz, and B. Milneritsch Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 30 2012 722 728
28. M.M. Regan, P. Neven, and A. Globbie-Hurder Assesment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years median follow-up Lancet Oncol 12 2011 1101 1108
29. G. Viale, M.M. Regan, and P. Dell'Orto Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial Ann Oncol 22 2011 2201 2207
30. C.J. Van de Velde, D. Rea, and C. Seynaeve Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial Lancet 377 2011 321 331
31. M. Dowsett, J. Salter, and L. Zabaglo Predictive algorithms for adjuvant therapy: TransATAC Steroids 76 2011 777 780